adamantane has been researched along with Polycystic Ovarian Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W; Tao, T; Wang, Y; Wu, P | 1 |
| Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL | 1 |
2 trial(s) available for adamantane and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Topics: Adamantane; Adult; Age of Onset; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Polycystic Ovary Syndrome; Prognosis; Prospective Studies | 2018 |
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot
Topics: Adamantane; Adiposity; Adolescent; Adult; Androgens; Biomarkers; Blood Glucose; Delayed-Action Preparations; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Combinations; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Pilot Projects; Polycystic Ovary Syndrome; Prediabetic State; Single-Blind Method; Time Factors; Treatment Outcome; Young Adult | 2017 |